Company's BV6 TCR Peptide Vaccine Induces An Immune Response in 80% of Vaccinated MS Patients
Monday April 30
Source: PR Newswire
CARLSBAD, Calif., April 30 /PRNewswire/ -- The Immune Response Corporation (Nasdaq: IMNR) announced the publication of data on their investigational T Cell Receptor (TCR) peptide vaccine for multiple sclerosis (MS) showing that it induced a specific response (stimulation index >5) in 80% of the patients treated. The objective of the Company's TCR vaccine program is to induce an immune response that inactivates the T cells thought to be pathogenic in MS. The article appears in the May issue of the Journal of Neuroscience Research. Eight of ten patients given five 300 microgram injections of the TCR peptides emulsified in Incomplete Freund's adjuvant (IFA) during the 48 week open label trial developed specific cell mediated responses as measured by both delayed-type hypersensitive (DTH) skin tests and lymphocyte proliferation assays (LPA). No responses against an irrelevant peptide were observed, and neurologic assessments, on average, remained stable during the trial.
"These data, from our Phase I MS trial completed in 1999, suggest that our BV6 peptide is highly immunogenic in MS patients, and justify its inclusion as part of a combination peptide vaccine in our future MS trials," said Richard M. Bartholomew, Ph.D., Executive Director of Research Operations for The Immune Response Corporation. "Based on data from previous clinical trials and over 160 pathogenic T cell clones isolated from many different MS patients, we believe that if commercially approved our TCR therapeutic vaccine combining BV5, BV6 and BV13.1 could potentially be used to treat approximately 90% of the patients suffering from MS."
Currently, the Company has a 60 patient Phase I/II TCR combination peptide vaccine study under way. The trial is being conducted at six centers located within the states of Washington and Oregon. The double blind, placebo-controlled trial will monitor safety, immunogenicity and clinical benefits.
The Immune Response Corporation is a biopharmaceutical company based in Carlsbad, California, developing immune-based therapies to induce specific T-cell responses for the treatment of HIV, autoimmune diseases and cancer. In addition, the Company is developing a targeted non-viral delivery technology for gene therapy, which is designed to enable the delivery of genes directly to the liver via intravenous injection.
NOTE: News releases are available through PR Newswire Company News On-Call fax service. For a menu of available news releases or to retrieve a specific release made by The Immune Response Corporation, please call 800-758-5804, extension 434675. Please retain these numbers for future reference. Company information can also be located on the Internet Web Site: http://www.imnr.com.
This news release
contains forward-looking statements. Actual results could vary materially
from those expected due to a variety of risk factors, including, but not
limited to, whether data generated from previous trials can be replicated
in future clinical trials, whether clinical trials will be successfully
concluded and whether an MS vaccine will be approved for marketing or be
successfully commercialized. Those factors are discussed more thoroughly
in The Immune Response Corporation's SEC filings, including but not limited
to its report on Form 10-K for the year ended December 31, 2000. The Company
undertakes no obligation to publicly release the result of any revisions
to these forward-looking statements, which may be made to reflect events
or circumstances after the date hereof or to reflect the occurrence of
Source: The Immune
Contact: investors, Kathy Lane, 760-771-2236, or media, Laura Hansen, Ph.D., 858-860-0266, both of The Immune Response Corporation